Tenpoint Therapeutics Ltd. and Visus Therapeutics, Inc. Join Forces, Building the Next Era of Best- and First-in-Class Ophthalmic Medicines [Yahoo! Finance]
Inozyme Pharma, Inc. (NASDAQ: INZY) is now covered by analysts at Raymond James. They set an "outperform" rating and a $26.00 price target on the stock.
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks [Yahoo! Finance]
Inozyme Pharma to Present at Upcoming Investor Conferences